Article in PDF
How to Cite
Citation Manager
Readers' Comments (0)
Audio Visual Article Statistics
Link
to PUBMED
Print this Article
Send to a Friend
Advertisers
Access Statistics Resources
Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."
Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011
Dr. Shankar P.R.
"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."
Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011 Anuradha
Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.
Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020
Case report
Full Version
Co-existence of Nodular Hyperplasia and Papillary Carcinoma Thyroid in a Case of Struma Ovarii: A Rare Occurrence
Correspondence Address :
Dr. Chhanda Das,
31, 1st Road, Eastern Park, Santoshpur, Kolkata-700075, West Bengal, India.
E-mail: chhhdas@gmail.com
Struma ovarii is a monodermal ovarian teratoma. This is an ovarian germ cell tumour with more than 50% ovarian tissue. It is a rare tumour, accounting for only 3-5% of all ovarian teratomas. Malignant transformation occurs very rarely, only in about 0.3% cases. The authors report a case of struma ovarii with a malignant transformation to papillary carcinoma thyroid. Not much information is present in the literature about this rare entity. Due to the rarity of this condition, there is a lack of uniformity of histological criteria of malignancy and its management is not universally accepted by physicians. Here, the authors present a rare case of struma ovarii with malignant transformation to papillary carcinoma thyroid. A 62-year-old female presented with a left ovarian mass. On histopathological examination of the surgical specimen of hysterectomy it was found that the ovary had a neoplastic growth with morphological features of papillary carcinoma thyroid. The final diagnosis was struma ovarii with papillary thyroid carcinoma. Postoperative period was uneventful for the patient. However, follow-up was not done.
Malignant, Monodermal, Ovary, Teratoma
The authors present a case of a 62-year-old woman presenting with heaviness of lower abdomen for more than three months. Initially, there weren’t any symptoms but gradually an ill-defined heaviness in the left lower abdomen developed with associated bloating and weight loss. On examination, no specific signs were present apart from a diffuse small swelling at the lower abdomen on palpation. Computed Tomography (CT) scan revealed a cystic solid left adnexal Space Occupying Lesion (SOL) with calcification measuring 6.0×5.7×5.4 cm, rest was within normal limit (Table/Fig 1). The radiological diagnosis was left adenexal cystic SOL. Suspecting an ovarian tumour, her serum Cancer antigen 125 (Ca) level was done. It came out to be within normal range (2.6 IU/mL). Blood work-ups for thyroid were within normal limit. Other tumour markers like Carcinoembryonic Antigen (CEA) was 4.3, β-hCG was 3.55, Alpha Feto Protein (AFP) was 0.9 IU/mL. Fine Needle Aspiration Cytology (FNAC) was tried from the left adnexal SOL under image guidance but results were not satisfactory because adequate amount of material was not there in the smears. This was not sufficient for a conclusive opinion. After relevant work-up, a laparotomy followed by total abdominal hysterectomy with salpingo-oophorectomy with omental biopsy was done under spinal anaesthesia. The surgical specimen was sent to the Department of Pathology for histopathology report.
Composite specimen of uterus, cervix with B/L adnexa was received. A globular left ovarian mass was found measuring 5×4×2 cm with cystic consistency (Table/Fig 2). On dissection, haemorrhagic areas with multiloculated cystic solid components were noted. Left sided fallopian tube was attached with this mass, other sided adnexa was unremarkable. Multiple relevant sections were taken from the specimen for tissue processing, paraffin embedding and Haematoxylin and Eosin (H&E) staining. Microscopic examination of sections from left adnexal SOL revealed ectopic thyroid tissue in the background of ovarian cytoarchitecture. This ectopic thyroid tissue was composed of more than 50% of the tumour parenchyma. This thyroid tissue showed features of focal nodular hyperplasia. Examination of more sections showed complex, randomly oriented branching papillae with fibrovascular core lined by cells with nuclear grooving, overlapping and optical clearing. Henceforth, the diagnosis of a monodermal struma ovarii with papillary thyroid carcinoma and focal nodular hyperplasia was framed (Table/Fig 3)a-d. Immunohistochemistry was done, which showed both nuclear positivity of Thyroid Transcription Factor-1 (TTF-1) and Paired Box Gene 8 (PAX8) that was further confirmatory of thyroid tissue in ovarian stroma (Table/Fig 4)a,b. Postoperative period was uneventful. The patient was eventually discharged. In subsequent Outpatient Department (OPD) visits, the patient was in a good state.
By definition, thyroid tissue in struma ovarii is more than 50% (1). In 1888 the presence of ectopic thyroid tissue in an ovarian teratoma was first described by Bottlin, but struma ovarii as a separate disease entity was recognised 40 years later by the work of Ludwig Pick (2). Malignant transformation is exceedingly rare. Only 5-10% of struma ovarii are histopathologically identical to differentiated thyroid carcinoma and recognised by the World Health Organisation (WHO) as Malignant Struma Ovarii (MSO) (3). Not much is known about this rare entity. In a review by Marcy PY et al., it was stated that there are less than 200 cases of such in the literature (4). Even after almost 100 years since its discovery, struma ovarii remains enigmatic, due to rarity of the condition. Malignant transformation of struma ovarii is even more rare. A number of cases reported as MSO in the past was stromal or insular carcinoid (5). The authors present here a case of struma ovarii in a 62-year-old woman manifesting as a left ovarian cystic mass. As per the literature, the average age of struma ovarii is 43 years (6). However, cases of struma ovarii in juvenile age of 10 years and in younger women (22 and 25 years) are also present. Most commonly occurring malignancy as per the literature is papillary carcinoma of the thyroid (7). The histopathological diagnosis is mainly based on typical papillary pattern and nuclear features like empty ground glass appearance and nuclear overlapping (8). In the present case, these microscopic features were clearly present. Nuclear features alone are not always sufficient for the diagnosis of malignancy; additional features like capsular invasion and peritoneal deposits are important as noted by Suzuki K et al., in their study on struma ovarii (9). In the present case, peritoneal deposition as well as capsular rupture was not present.
However, there was strong nuclear positivity of TTF-1, which plays a cardinal role for the differentiation of thyroid follicular cells. It is also expressed in numerous tissues such as posterior pituitary and hypothalamus, in addition to thyroid (9).
As stated by other authors, PAX8, TTF-1 and Thyroglobulin (TG) immunohistochemical expression can be used to differentiate MSO from other ovarian neoplasms, but it is not clear whether these are of help in differentiating malignant from benign struma ovarii (10). Sections from the tumour demonstrated strong nuclear staining for PAX8. PAX8 belongs to the paired box gene family, which is a important gene in organogenesis of several systems like thyroid, Mullerian system, and renal system. PAX8 positivity indicates its thyroid origin (11). As stated earlier, relevant tumour markers were not contributory. CA125 is a marker for MSO but as per the literature, it is not effective due to its non specificity (10). In this case CA125 was only 2.6 IU/mL corroborating with past reports. Whether histochemical markers like Human Bone Marrow Endothelial cell marker-1 (HBME-1), specific cytokeratins like Cytokeratin 19 (CK19), Rearranged During Transfection (RET) are of utility in diagnosis of MSO needs further investigation and research (12). Due to the rarity of this entity, its immunohistochemcal profile has not been distinctively established. Marti JL et al., in their case series reported four cases of struma ovarii. Among these four cases, three cases had papillary thyroid carcinoma in the ovarian SOL. One case however had follicular thyroid carcinoma. They also reviewed 53 past reported cases of struma ovarii with well differentiated thyroid carcinoma. Among these 53 cases, papillary thyroid cancer was the most common histology (74%), followed by follicular variant of papillary (21%), and follicular thyroid cancer (5%). Therefore, these findings are corroborative with the present case. Metastasis was also not present in these cases, which was similar to the present case, where there was no evidence of metastatic involvement (13).
Struma ovarii is a rare condition. As it is an elusive condition, not much information is present in the literature. Uniform histological criteria for malignancy are lacking. In the present case, after surgical excision the diagnosis was made as struma ovarii with a component of papillary thyroid carcinoma. Thus, diligent sampling of ovarian growth and careful microscopic examination is necessary for diagnosis. Further research is needed to identify the pathogenesis of this condition.
DOI: 10.7860/JCDR/2023/63890.18484
Date of Submission: Mar 08, 2023
Date of Peer Review: Apr 17, 2023
Date of Acceptance: Jul 26, 2023
Date of Publishing: Sep 01, 2023
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. Yes
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Mar 20, 2023
• Manual Googling: Apr 28, 2023
• iThenticate Software: Jul 24, 2023 (5%)
ETYMOLOGY: Author Origin
EMENDATIONS: 7
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase
- EBSCOhost
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)
- www.omnimedicalsearch.com